Hayashi-Takagi Akiko
Laboratory of Medical Neuroscience, Institute for Molecular and Cellular Regulation, Gunma University, Maebachi, Gunma 371-8512, Japan; PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.
Neurosci Res. 2017 Jan;114:3-8. doi: 10.1016/j.neures.2016.09.001. Epub 2016 Sep 12.
Schizophrenia is a chronic, severe, and disabling brain disorder, with an estimated lifetime prevalence of 0.7%. Despite its relatively low prevalence, the onset of schizophrenia usually occurs early in life, resulting in a severe lifelong disability for patients and increasing the economic and care burden on their families. This makes schizophrenia one of the most catastrophic mental illnesses. Although the etiology of schizophrenia remains poorly understood, clinical, genetic, and pharmacological studies have indicated that its pathophysiology involves synaptic disturbances. Here, I review the evidence suggesting synaptic disturbance as the causal pathophysiology of schizophrenia and discuss the possible application of synaptic intervention as a novel therapeutic strategy for schizophrenia.
精神分裂症是一种慢性、严重且致残的脑部疾病,估计终生患病率为0.7%。尽管其患病率相对较低,但精神分裂症通常在生命早期发病,给患者带来严重的终生残疾,并增加其家庭的经济和护理负担。这使得精神分裂症成为最具灾难性的精神疾病之一。尽管精神分裂症的病因仍知之甚少,但临床、遗传学和药理学研究表明,其病理生理学涉及突触紊乱。在此,我回顾了表明突触紊乱是精神分裂症因果病理生理学的证据,并讨论了突触干预作为精神分裂症新型治疗策略的可能应用。